['respiratory syncytial virus infections']
['suptavumab 30 mg/kg', 'placebo matched to suptavumab', 'suptavumab 30 mg/kg- 1 dose', 'suptavumab 30 mg/kg - 2 doses']

        Key Inclusion Criteria:

          1. Preterm, otherwise healthy male or female infant who is ≤6 months of age at the time
             of the first dose (i.e., infant must be treated on or before their 6 month birthday)

          2. Gestational age is ≤35 weeks, 6 days at birth

          3. Parent(s) or legal guardian(s) of the infant is able to understand the study
             requirements and willing to provide informed consent

        Key Exclusion Criteria:

          1. Eligible, recommended and have access to receive palivizumab per AAP or other local
             guidelines, standard practice, or by their healthcare provider

          2. History of CLD defined as requirement of supplemental oxygen for 28 days after birth

          3. Known hemodynamically significant congenital heart disease

          4. Known immunodeficiency, neuromuscular disease, or congenital abnormalities of the
             airway

          5. Known renal or hepatic dysfunction

          6. Major congenital malformations, including congenital cleft palate, cytogenetic
             abnormalities, or serious chronic disorders

          7. Known or suspected impairment of immunological functions or autoimmune diseases

          8. History of anaphylaxis

          9. Previously received palivizumab or any other investigational RSV prophylaxis or
             vaccine product

         10. Previous reaction to IV immunoglobulin, blood products or other foreign proteins,
             including vaccines and monoclonal antibodies

        Note: Other inclusion and exclusion criteria apply
      